InMode's Fight Against Counterfeit Devices
InMode Ltd., a leading player in the medical technology domain, has recently achieved a significant victory in the legal battle against counterfeit products. On May 6, 2025, the United States District Court for the Central District of California granted a default judgment in favor of InMode against sellers on DHGate who were distributing counterfeit Morpheus8 radio frequency microneedling devices and needle cartridges.
Background of the Case
The court's ruling comes as a result of InMode's ongoing efforts to combat fraudulent trade practices that jeopardize both the company's trademark rights and, more importantly, patient safety. The decision entails a permanent injunction that not only halts the sales of the counterfeit products but also freezes the assets linked to the offending sellers.
According to Moshe Mizrahy, CEO of InMode, this initiative reinforces the company's strict policy against fraudulent activities. Mizrahy emphasized, "InMode maintains a zero-tolerance policy towards fraudulent business practices, including counterfeit goods and for any platforms or sellers who are using, selling, or distributing false products." This commitment underlines a broader dedication to safeguarding consumers from the dangers presented by unauthorized and unsafe medical devices.
Legal Implications and Reactions
The ruling addressed multiple claims against the defendants, including trademark infringement and unfair competition under California law. By favoring InMode on all claims, the court affirmed the importance of protecting trademarked products against unauthorized use, thereby enhancing consumer confidence in medical treatments.
Alongside freezing assets of the sellers involved, InMode's victory will affect any current listings of the disputed devices, putting a halt to counterfeit trades that have been damaging to both the brand and, more critically, public safety.
Verified Provider Program
In an additional effort to ensure safety for patients, InMode has initiated a Verified Provider Program. This program allows certified clinics to demonstrate their authenticity and confirm their use of genuine Morpheus8 technology. This initiative not only facilitates the identification of legitimate providers but also highlights their commitment to delivering safe, consistent results.
Patients seeking reliable and quality care from authorized InMode providers can easily locate appropriate clinics through the Find a Provider tool available on InMode's official website. This service is vital for patients across the United States and Canada who are interested in benefiting from Morpheus8 treatments without the risks associated with counterfeit devices.
Conclusion
Inmode's success in achieving this injunction is pivotal for the company. It highlights both a rigorous commitment to ethical business practices and an assurance of safety for consumers seeking medical treatments. As the landscape of medical technology continues to evolve, InMode is poised to remain at the forefront in maintaining the integrity of its products and protecting its clientele against deceitful practices. To learn more about InMode, their innovative medical technologies, and how to find authorized providers, visit their website at
www.inmodemd.com.